anti-HER2 x CD3 bispecific antibody

Anti-HER2 x CD3 bispecific antibodies represent a class of cancer immunotherapies designed to bridge T cells and tumor cells to induce immune-mediated cell death. These biologics are engineered to simultaneously bind to the Human Epidermal Growth Factor Receptor 2 (HER2) on the surface of cancer cells and the CD3 subunit of the T-cell receptor complex on T-lymphocytes. This dual engagement facilitates the formation of a cytolytic synapse, leading to the activation and proliferation of T cells and the subsequent release of cytotoxic granules, such as perforin and granzymes, which induce apoptosis in the HER2-expressing tumor cells. This mechanism, known as T-cell redirection, allows for potent tumor cell killing that is independent of major histocompatibility complex (MHC) recognition. Several candidates in this class, including M802 and Genentech's HER2-TDB, have entered clinical trials for the treatment of HER2-positive advanced malignancies, such as breast, gastric, and colorectal cancers.

Other names

HER2 x CD3 bispecific antibodyHER-2 x CD3 bispecific antibodyHER 2 x CD3 bispecific antibodyHER2/CD3 T-cell dependent bispecific antibodyHER2-TDBHER-2-TDBHER 2-TDBHER2-targeted T-cell engagerHER-2-targeted T-cell engagerHER 2-targeted T-cell engager